Overexpression of MMP-9 and hif-1α in breast cancer cells under hypoxic conditions

Journal of Breast Cancer

Volumn 14, Issue 2, 2011, Pages 88-95

  Choi, Jae Young ^a   Jang, Yeon Soo ^b   Min, Sun Young ^c   Song, Jeong Yoon ^c  

^a Gangnam Yeil Clinic   (South Korea)

^b Eulji University School of Medicine   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

Author keywords

Angiogenesis; Breast neoplasms; Hypoxia inducible factor 1 alpha subunit; Matrix metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERSTITIAL COLLAGENASE; LUCIFERASE; RAS PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CELL HYPOXIA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN STABILITY; ZYMOGRAPHY;

EID: 79959845729     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2011.14.2.88     Document Type: Article

References (30)

1. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
2. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003;94:1021-8.
3. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9 Suppl 5:10-7.
4. Vaupel P, Kelleher DK, Höckel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28(2 Suppl 8):29-35.
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
6. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) 2004;19:176-82.
7. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8.
8. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72.
9. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 2000;106:809-12.
10. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8(4 Suppl):S62-7.
11. Freije JM, Balbín M, Pendás AM, Sánchez LM, Puente XS, López-Otín C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107.
12. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
13. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
14. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7.
15. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999;189:161-8.
16. Jensen RL, Ragel BT, Whang K, Gillespie D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol 2006;78:233-47.
17. Bos R, van Diest PJ, van der Groep P, Shvarts A, Greijer AE, van der Wall E. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related. Breast Cancer Res 2004;6:R450-9.
18. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97:1573-81.
19. Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, et al. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res 2004; 6:R191-8.
20. Pritchard SC, Nicolson MC, Lloret C, McKay JA, Ross VG, Kerr KM, et al. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep 2001;8:421-4.
21. Zhang X, Zhu S, Luo G, Zheng L, Wei J, Zhu J, et al. Expression of MMP-10 in lung cancer. Anticancer Res 2007;27(4C):2791-5.
22. Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, et al. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 2000;86:204-7.
23. Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, et al. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res 2007; 27(3B):1519-25.
24. Canning MT, Postovit LM, Clarke SH, Graham CH. Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res 2001;267:88-94.
25. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003;63:1138-43.
26. Hernández-Alcoceba R, del Peso L, Lacal JC. The Ras family of GTPases in cancer cell invasion. Cell Mol Life Sci 2000;57:65-76.
27. Nguyen M, McCombs MM, Ghandehari S, Kim A, Wang H, Barsky SH, et al. An update on core needle biopsy for radiologically detected breast lesions. Cancer 1996;78:2340-5.
28. Klimberg VS. Advances in the diagnosis and excision of breast cancer. Am Surg 2003;69:11-4.
29. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004.
30. Giatromanolaki A, Koukourakis MI, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res 2004; 10:7972-7.